Tabelecleucel

L01XL09(WHO) EU:Rx-only DB17072 G3NJ7M8N4H D11146 Tabelecleucel, sold under the brand nameEbvallo, is amedicationused for the treatment ofEpstein-Barr virus positive post-transplant lymphoproliferative disease(EBV+ PTLD).Tabelecleucel is anallogeneic, EBV-specificT-cellimmunotherapy which targets and eliminates EBV-infected cells in ahuman leukocyte antigen(HLA)-restricted manner.It is made of cells of the immune system called T-cells that have been taken from a donor (allogeneic) and are then mixed with EBV-infected B-cells from the same donor. The most common side effects include fever, diarrhea, fatigue, nausea (feeling sick), anemia (low red blood cell count), reduced appetite, hyponatremia (low sodium levels in the blood), abdominal pain, low white blood cell count, including neutrophils (white blood cells that fight infections), elevated blood levels of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase (indicators of potential liver damage), constipation, hypoxia (low blood oxygen levels), dehydration, hypotension (low blood pressure), nasal congestion, and rash. Tabelecleucel was approved for medical use in the European Union in December 2022.